Hantrakun Nonthakorn, Sinsakolwat Peampost, Tantiworawit Adisak, Rattarittamrong Ekarat, Rattanathammethee Thanawat, Hantrakool Sasinee, Piriyakhuntorn Pokpong, Punnachet Teerachat, Niprapan Piangrawee, Wongtagan Ornkamon, Chaiwarith Romanee, Norasetthada Lalita, Chai-Adisaksopha Chatree
Division of Hematology, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand.
Division of Infectious Diseases and Tropical Medicine, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand.
Vaccines (Basel). 2023 Mar 17;11(3):692. doi: 10.3390/vaccines11030692.
Anti-platelet factor 4 (anti-PF4) antibodies were identified as pathogenic antibodies for vaccine-induced immune thrombocytopenia and thrombosis (VITT) in subjects receiving ChAdOx1 nCoV-19 vaccinations. We performed a prospective cohort study to determine the prevalence of anti-PF4 and the effect of the ChAdOx1 nCoV-19 vaccine on anti-PF4 in healthy Thai subjects. Anti-PF4 antibodies were measured before and four weeks after receiving the first vaccination. Participants with detectable antibodies were scheduled for repeat anti-PF4 analysis at 12 weeks after the second vaccination. Of 396 participants, ten participants (2.53%; 95% confidence interval [CI], 1.22-4.59) were positive for anti-PF4 before receiving vaccinations. Twelve people (3.03%; 95% CI, 1.58-5.23) had detectable anti-PF4 after the first vaccination. There was no difference in the optical density (OD) values of anti-PF4 antibodies when comparisons were made between pre-vaccination and four weeks after the first vaccination ( = 0.0779). There was also no significant difference in OD values in participants with detectable antibodies. No subjects experienced thrombotic complications. Pain at the injection site was associated with an increased risk of being anti-PF4 positive at an odds ratio of 3.44 (95% CI, 1.06-11.18). To conclude, the prevalence of anti-PF4 was low in Thais and did not significantly change over time.
抗血小板因子4（anti-PF4）抗体被确定为接种ChAdOx1 nCoV-19疫苗的受试者发生疫苗诱导的免疫性血小板减少症和血栓形成（VITT）的致病性抗体。我们进行了一项前瞻性队列研究，以确定泰国健康受试者中抗PF4的流行率以及ChAdOx1 nCoV-19疫苗对其的影响。在接种第一剂疫苗前和接种后四周测量抗PF4抗体。抗体检测呈阳性的参与者计划在接种第二剂疫苗后12周进行抗PF4重复分析。在396名参与者中，10名参与者（2.53%；95%置信区间[CI]，1.22-4.59）在接种疫苗前抗PF4呈阳性。12人（3.03%；95%CI，1.58-5.23）在接种第一剂疫苗后可检测到抗PF4。在比较接种疫苗前和接种第一剂疫苗后四周时，抗PF4抗体的光密度（OD）值没有差异（=0.0779）。抗体检测呈阳性的参与者的OD值也没有显著差异。没有受试者出现血栓并发症。注射部位疼痛与抗PF4呈阳性的风险增加相关，比值比为3.44（95%CI，1.06-11.18）。总之，泰国人中抗PF4的流行率较低，且随时间没有显著变化。
